Diligence report Industrials / sustainable specialty chemicals and biomanufacturing Private unicorn / late-stage venture-backed climate and industrial technology company

Solugen

Solugen Startup Diligence Research Report

Solugen is attempting to displace fossil-derived specialty chemicals with Bioforge-produced molecules. Public evidence supports technology positioning, financing and scale-up partnerships; investment reliance requires private financial, cap-table, customer, plant, legal/EHS and technical diligence.

Company profile

Solugen Startup Diligence Research Report

Solugen passes the public eligibility screen as an active private unicorn: CB Insights lists it at $2B and public company/CNBC sources show active operations, hiring, partnerships and no public IPO/acquisition/shutdown found in this review. The largest underwriting gaps are financial quality, customer concentration/offtake economics and Bioforge Marshall scale-up execution.

Website: solugen.com
Sector: Industrials / sustainable specialty chemicals and biomanufacturing
Geography: United States / Houston, Texas
Stage: Private unicorn / late-stage venture-backed climate and industrial technology company
Known aliases: Solugen, Inc., Bioforge, Solugen Bioforge
Report version: 1.0
Timezone: UTC

Executive summary

Strengths

CB Insights lists Solugen at $2B and CNBC reported a $1.8B+ 2021 valuation.
Company and CNBC sources describe Bioforge using bio-based feedstocks, engineered enzymes and metal catalysts.
ADM, DOE, Kurita and Sasol announcements support partner/scale-up signals.

Risks

Financial opacity and valuation support.
Bioforge Marshall scale-up and DOE conditions.
Customer concentration, offtake and channel economics opacity.

Gaps

Audited financial statements and management accounts
Fully diluted cap table and financing terms
Revenue by customer and concentration
ADM feedstock and supplier contracts
Bioforge Marshall project plan and budget
SKU pricing and unit economics

Recommended next steps

Open finance/cap-table data room and reconcile CB/CNBC valuation markers to primary documents.
Run customer/offtake diligence on top accounts, partner relationships and channel economics.
Conduct technical and plant diligence covering Bioforge yields, uptime, cost curves, LCA, IP/FTO and Marshall project controls.
Have counsel review litigation, SEC/Form D records, permits, TRI/EHS records, insurance and material contracts.

Risk register

high high likelihood

R-001: Financial opacity and valuation support

No audited financials, ARR, gross margin, runway or full cap table are public.

Diligence request: Open finance and capitalization data room.

high medium likelihood

R-002: Bioforge Marshall scale-up and project finance

500,000 sq ft/120 KTA Marshall ramp, ADM feedstock and DOE conditions create execution risk.

Diligence request: Review EPC plan, cost-to-complete, permits, feedstock contract and DOE conditions.

high medium likelihood

R-003: Customer concentration and offtake opacity

Named partner signals do not disclose customer revenue, churn, offtake or channel economics.

Diligence request: Obtain customer revenue, contracts, churn, renewals and references.

medium high likelihood

R-008: Incumbent competition and adoption friction

Solugen targets entrenched chemical markets with qualification and switching barriers.

Diligence request: Validate win/loss, competitor pricing and qualification cycles.

medium medium likelihood

R-004: EHS and regulatory exposure

Chemical manufacturing, TRI reporting and DOE environmental conditions require EHS review.

Diligence request: Obtain permits, OSHA logs, ECHO/TRI, audits and agency correspondence.

medium medium likelihood

R-005: Litigation and contract disputes

Verdan docket and historical M3 litigation require counsel review.

Diligence request: Provide full docket, pleadings, reserves and settlement posture.

medium medium likelihood

R-006: Technology/IP defensibility and scale economics

Patents and R&D narrative are public; FTO, trade secrets, yields and cost curves are private.

Diligence request: Run technical, plant, LCA and IP/FTO review.

medium medium likelihood

R-007: Management depth and hiring/retention opacity

Leadership and job postings are public; org depth, comp and turnover are private.

Diligence request: Review org chart, compensation, attrition and succession.

Chapter 01

01Financial Information

Financial Information diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-001 EC-003 EC-004 EC-005 EC-008 EC-009

I.A Annual and quarterly financial information for the past three years

not publicly verifiable confidence: low

Annual and quarterly financial information for the past three years: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-003 EC-004

Evidence gaps

Private records needed for annual and quarterly financial information for the past three years are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering annual and quarterly financial information for the past three years.

Public revenue / unit-economic signals
item	public evidence	verification status	diligence request
Historical revenue growth	2019 release says revenue grew nearly 10x from multiple multi-million dollar oil/gas contracts.	partially_verified	audited revenue, customer schedule, gross margin
Production scale	CNBC reported Bioforge produced 10,000 metric tons/year in 2021.	partially_verified	uptime, yield, utilization, cost curves
ARR/EBITDA/cash burn	No public statements found.	not_publicly_verifiable	management accounts and board model

I.B Financial Projections

not publicly verifiable confidence: low

Financial Projections: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-008 EC-009

Evidence gaps

Private records needed for financial projections are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering financial projections.

I.C Capital Structure

not publicly verifiable confidence: low

Capital Structure: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-001 EC-003 EC-005

Evidence gaps

Private records needed for capital structure are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering capital structure.

Capital structure / ownership snapshot
stakeholder	public position	evidence	diligence caveat
Founders	Gaurab Chakrabarti CEO/co-founder; Sean Hunt CTO/co-founder	Leadership/CNBC	ownership and vesting not public
Investors	Fifty Years, Refactor, Temasek, GIC, Baillie Gifford, BlackRock funds, Carbon Direct, Founders Fund and others	CB/CNBC/Series B release	preferences, board rights and side letters not public
SEC Form D issuer	Solugen, Inc. CIK 0001756965	Form D filings 2018-2021	not a full cap table
DOE/lenders	$213.6M conditional loan guarantee	DOE announcement	definitive terms not public

I.D Other financial information

partially verified confidence: medium

Other financial information: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-001 EC-003 EC-004 EC-005 EC-009

Evidence gaps

Private records needed for other financial information are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering other financial information.

Public funding-round history
date	round	amount	investors	valuation or terms	verification status
2018-10	Prior financing referenced in Series B release	$13.5M	not fully public	not_publicly_verifiable	partially_verified
2019-05-22	Series B	$32M	Founders Fund, Y Combinator, Refactor, Fifty Years, KdT	not_publicly_verifiable	verified
2021-09-09/10	Venture financing/unicorn marker	$357M	GIC, Baillie Gifford, Temasek, BlackRock funds, Carbon Direct and others	north of $1.8B CNBC; $2B CB Insights	verified
2024-06-13	DOE conditional loan guarantee	$213.6M	DOE LPO / lenders	conditional project financing	partially_verified

Security terms and cap table are private.

Funding and facility timeline Public financing and facility milestones.

Funding and valuation trajectory Bar chart of disclosed financing and valuation markers.

Chapter 02

02Products

Products diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-006 EC-007 EC-008 EC-010 EC-012

II.A Description of each product

partially verified confidence: medium

Description of each product: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-006 EC-007 EC-008 EC-010 EC-012

Evidence gaps

Private records needed for description of each product are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering description of each product.

Product / market matrix
product or solution	market	public features	verification status
Bioforge platform	industrial chemicals	bio-based feedstocks, engineered enzymes, metal catalysts	verified
Verza360 / organic-acid chelants	oil/gas and produced water	iron control and operational performance positioning	partially_verified
AcquaCore / water-treatment additives	industrial water treatment	scale/corrosion and low-phosphorus positioning	partially_verified
NutriValent / agricultural complexing agents	agriculture	bio-based complexing agents for plant nutrition	partially_verified
Marshall organic acids/new molecules	water, agriculture, energy, construction, cleaning, personal care	ADM-linked expansion	partially_verified

Pricing comparison and margin diligence
item	public evidence	verification status	diligence request
Public list prices	No price sheet found.	not_publicly_verifiable	price book, discounts, freight/rebates
Cost/performance claims	Company/partner releases claim cost-competitive, high-performance products.	partially_verified	benchmarks, customer pilots, gross margin by SKU
Incumbent alternatives	Pages position products against incumbent chemistries.	partially_verified	win/loss and competitor pricing

Bioforge process architecture Public Bioforge process dependencies.

Chapter 03

03Customer Information

Customer Information diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-003 EC-004 EC-006 EC-008 EC-009 EC-010

III.A Top customers by application

partially verified confidence: medium

Top customers by application: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-003 EC-004 EC-010

Evidence gaps

Private records needed for top customers by application are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering top customers by application.

Publicly known customers and case studies
customer or logo	use case	public evidence	verification status	gap
Water-treatment service provider network	BioChelate	CNBC says BioChelate sold through service-provider network.	partially_verified	accounts/revenue private
Oil/gas contracts	water/oilfield chemicals	2019 release cites multiple multi-million dollar contracts.	partially_verified	names/current status private
Kurita	industrial water treatment products	collaboration and Tower NG reference.	partially_verified	revenue not disclosed
Sasol	care/cleaning ingredient evaluation	evaluation announcement.	partially_verified	outcome not disclosed

Partner/customer concentration proxy Named public relationships, not revenue concentration.

III.B Strategic relationships

verified confidence: medium

Strategic relationships: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-008 EC-009 EC-010

Evidence gaps

Private records needed for strategic relationships are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering strategic relationships.

Strategic relationships and partnerships
partner	nature	public evidence	risk or gap
ADM	feedstock/site partner	Marshall facility adjacent to ADM corn complex; ADM dextrose.	terms/exclusivity private
DOE LPO	conditional loan guarantee	$213.6M conditional commitment.	conditions/final close private
Kurita America	water product development	carbon-negative water-treatment collaboration.	volumes/margins private
Sasol Chemicals	care chemicals evaluation	Sasol will evaluate Solugen materials.	evaluation only

III.C Revenue by customer

not publicly verifiable confidence: low

Revenue by customer: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-010

Evidence gaps

Private records needed for revenue by customer are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering revenue by customer.

III.D Significant relationships severed within the last two years

not publicly verifiable confidence: low

Significant relationships severed within the last two years: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-010

Evidence gaps

Private records needed for significant relationships severed within the last two years are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering significant relationships severed within the last two years.

III.E Top suppliers

partially verified confidence: medium

Top suppliers: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-006 EC-008 EC-009

Evidence gaps

Private records needed for top suppliers are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering top suppliers.

Top supplier / infrastructure dependencies
supplier or dependency	role	public evidence	concentration risk
ADM Marshall corn complex	dextrose and site logistics	150M lbs dextrose/year and two pipelines at full production.	high unless alternatives/price protections exist
Corn syrup/dextrose wet mills	bio-based feedstock	CNBC says Solugen buys corn syrup from Iowa wet mills.	commodity/logistics risk
Enzyme/catalyst production	core manufacturing inputs	technology page describes fermentation and catalyst testing.	internal scale/contamination risk

Chapter 04

04Competition

Competition diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-006 EC-007 EC-010 EC-011

IV.A Competitive landscape by market segment

partially verified confidence: medium

Competitive landscape by market segment: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-006 EC-007 EC-010 EC-011

Evidence gaps

Private records needed for competitive landscape by market segment are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering competitive landscape by market segment.

Competitor comparison matrix
competitor or group	segment	overlap	solugen position	evidence
BASF / Dow / Sinopec examples	incumbent chemicals	fossil-derived alternatives	bio-based lower-carbon alternative	CNBC market context
Water-treatment chemical suppliers	chelants/corrosion/scale additives	AcquaCore/Kurita products	bio-based product claims	Solugen/Kurita
Synthetic-biology peers	bio-based molecules	platform scale-up	publicly cited manufacturing/sales scale	CNBC contrast with Zymergen

Basis-of-competition scoring
axis	solugen public position	competitor position	evidence strength	diligence need
cost/performance	cost-competitive/high-performance claims	incumbent scale	medium	ASP, margins, pilots
carbon footprint	lower-carbon/carbon-negative positioning	fossil-derived processes	medium	third-party LCA
scale	Houston commercial plus Marshall 120 KTA plan	global incumbent plants	medium	uptime/capex/ramp
distribution	partners/service providers	global direct distribution	low	channel economics

Competitive positioning map Position Solugen by scale and lower-carbon differentiation.

Chapter 05

05Marketing, Sales, and Distribution

Marketing, Sales, and Distribution diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-003 EC-007 EC-008 EC-010 EC-014

V.A Strategy and implementation

partially verified confidence: medium

Strategy and implementation: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-003 EC-007 EC-008 EC-010

Evidence gaps

Private records needed for strategy and implementation are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering strategy and implementation.

Distribution channels and GTM motions
channel	region	public evidence	open question
direct/partner industrial sales	U.S.	market pages use contact/sample motions	sales team, quotas, CAC
service-provider network	U.S.	CNBC BioChelate network	active distributors and economics
strategic commercialization	ADM/Kurita/Sasol	partner announcements	commitments/exclusivity

Public marketing-signal summary
signal	evidence	strength	diligence gap
CNBC Disruptor 50	ranked #36 in 2024 private-company list	medium	lead impact unknown
Partner announcements	ADM, Kurita, Sasol	medium	revenue conversion unknown
Technical/product content	Bioforge and market pages	medium	traffic/conversion unknown

GTM channel-mix proxy Public GTM signal counts, not revenue weights.

V.B Major Customers

not publicly verifiable confidence: low

Major Customers: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-010

Evidence gaps

Private records needed for major customers are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering major customers.

V.C Principal avenues for generating new business

partially verified confidence: medium

Principal avenues for generating new business: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-003 EC-007 EC-010

Evidence gaps

Private records needed for principal avenues for generating new business are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering principal avenues for generating new business.

V.D Sales force productivity model

not publicly verifiable confidence: low

Sales force productivity model: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-014

Evidence gaps

Private records needed for sales force productivity model are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering sales force productivity model.

V.E Ability to implement marketing plan with current and projected budgets

not publicly verifiable confidence: low

Ability to implement marketing plan with current and projected budgets: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-010

Evidence gaps

Private records needed for ability to implement marketing plan with current and projected budgets are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering ability to implement marketing plan with current and projected budgets.

Chapter 06

06Research and Development

Research and Development diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-008 EC-010 EC-011 EC-012 EC-013

VI.A Description of R&D organization

verified confidence: medium

Description of R&D organization: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-012 EC-013

Evidence gaps

Private records needed for description of r&d organization are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering description of r&d organization.

Key R&D personnel / capabilities
capability or person	role	public evidence	diligence question
Gaurab Chakrabarti	CEO/co-founder; biology/enzymology	MD/PhD, founded Solugen in 2016	key-person/succession
Sean Hunt	CTO/co-founder; catalysts/Bioforge	MIT PhD; process scale-up	CTO dependency
Enzyme/catalyst platform	core R&D	AI libraries, screening, fermentation, pilot plant	yield/FTO/reproducibility
Ken Keckler	Chief Engineer	Bioforge Marshall front-end design	project controls

R&D capability architecture R&D-to-scale-up public capability map.

VI.B New Product Pipeline

partially verified confidence: medium

New Product Pipeline: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-008 EC-010 EC-011

Evidence gaps

Private records needed for new product pipeline are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering new product pipeline.

Public product / research pipeline
project	status	expected timing	public evidence	verification status
Bioforge Marshall	construction/planned production	fall 2025 per public releases	500,000 sq ft facility	partially_verified
new organic acids/molecules	planned/development	not_publicly_verifiable	ADM release	partially_verified
carboligation/CO2-to-products concepts	aspirational	not_publicly_verifiable	CNBC founder comments	partially_verified
carbon-negative water-treatment products	partner development	not_publicly_verifiable	Kurita collaboration	partially_verified

Chapter 07

07Management and Personnel

Management and Personnel diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-005 EC-008 EC-009 EC-013 EC-014

VII.A Organization Chart

partially verified confidence: medium

Organization Chart: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-013

Evidence gaps

Private records needed for organization chart are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering organization chart.

Public leadership org chart Publicly verified leadership roles.

VII.B Historical and projected headcount by function and location

partially verified confidence: medium

Historical and projected headcount by function and location: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-008 EC-009 EC-014

Evidence gaps

Private records needed for historical and projected headcount by function and location are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering historical and projected headcount by function and location.

Headcount and hiring signals
function or site	public signal	source	verification status	diligence request
Houston accounting/legal/operations/R&D	multiple open roles	Breezy	verified_point_in_time	headcount, vacancies, turnover
Defense/external affairs	defense business ops role with salary band	Breezy	verified_point_in_time	government-contract staffing
Bioforge Marshall	up to 100 construction jobs and >50/56 full-time jobs	ADM/DOE releases	partially_verified	staffing/training plan

Public hiring and job-creation anchors Visible openings and public Marshall job anchors.

VII.C Senior management biographies

verified confidence: medium

Senior management biographies: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-013

Evidence gaps

Private records needed for senior management biographies are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering senior management biographies.

Senior management roster
name	role	public background	verification status
Gaurab Chakrabarti	CEO/co-founder	physician-scientist, MD/PhD, founded Solugen in 2016	verified
Sean Hunt	CTO/co-founder	chemical engineer, MIT PhD, process/catalyst focus	verified
Chuck (surname not captured)	COO	operations/supply-chain leadership at Apple, Tesla, Nike, Zoom	partially_verified
James Begeal	President, Energy & Water	25+ years chemicals; Clariant/Baker Hughes/Nexgen/Foremark	partially_verified
Ken Keckler	Chief Engineer	45 years refining/chemicals; Bioforge Houston/Marshall	partially_verified

VII.D Compensation arrangements

not publicly verifiable confidence: low

Compensation arrangements: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-014

Evidence gaps

Private records needed for compensation arrangements are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering compensation arrangements.

VII.E Incentive stock plans

not publicly verifiable confidence: low

Incentive stock plans: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-005

Evidence gaps

Private records needed for incentive stock plans are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering incentive stock plans.

VII.F Significant employee relations problems, past or present

not publicly verifiable confidence: low

Significant employee relations problems, past or present: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-014

Evidence gaps

Private records needed for significant employee relations problems, past or present are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering significant employee relations problems, past or present.

VII.G Personnel Turnover

not publicly verifiable confidence: low

Personnel Turnover: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-013 EC-014

Evidence gaps

Private records needed for personnel turnover are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering personnel turnover.

Departures / turnover signals
item	public evidence	verification status	diligence request
Executive departures	No comprehensive schedule found.	not_publicly_verifiable	two-year departures and regretted attrition
Role transition	Sean Liu previously led finance and is now strategic advisor per leadership page.	partially_verified	finance succession and turnover history
Retention/employee relations	No detailed employee-relations data public.	not_publicly_verifiable	HR claims, retention and safety training records

Chapter 08

08Legal and Related Matters

Legal and Related Matters diligence uses public evidence where available and marks remaining checklist items not_publicly_verifiable.

EC-008 EC-009 EC-010 EC-015 EC-016 EC-017 EC-018

VIII.A Pending lawsuits against the Company

partially verified confidence: medium

Pending lawsuits against the Company: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-016

Evidence gaps

Private records needed for pending lawsuits against the company are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering pending lawsuits against the company.

Pending lawsuits against the company
case	court or docket	status	public evidence	diligence request
Verdan Procurement and Consulting d/b/a VPC Chemicals v. Solugen et al	S.D. Tex. 4:25-cv-00010	notice of removal Jan 2025; remand denied Mar 2025 per aggregator; current disposition not fully verified	PACERMonitor page	pleadings, damages, reserves, counsel view
Other pending matters	not_publicly_verifiable	not exhaustively searched	limited public search	full litigation schedule

VIII.B Pending lawsuits initiated by Company

partially verified confidence: medium

Pending lawsuits initiated by Company: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-017

Evidence gaps

Private records needed for pending lawsuits initiated by company are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering pending lawsuits initiated by company.

Pending lawsuits initiated by company
case	court or docket	status	public evidence	diligence relevance
Solugen, Inc. v. M3 Chemical Group, LLC and James Mulloy	S.D. Tex. 4:19-cv-01658	2021 summary judgment in part opinion	Justia Law	final disposition/settlement needed
Other plaintiff matters	not_publicly_verifiable	not exhaustively searched	none verified	counsel schedule needed

VIII.C Environmental and employee safety issues and liabilities

partially verified confidence: medium

Environmental and employee safety issues and liabilities: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-009 EC-018

Evidence gaps

Private records needed for environmental and employee safety issues and liabilities are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering environmental and employee safety issues and liabilities.

VIII.D Material patents, copyrights, licenses, and trademarks

partially verified confidence: medium

Material patents, copyrights, licenses, and trademarks: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-015

Evidence gaps

Private records needed for material patents, copyrights, licenses, and trademarks are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering material patents, copyrights, licenses, and trademarks.

Material IP assets
asset	index	status	public evidence	diligence request
iron sulfide dissolution compositions/methods	Justia patents	patent 12624276 listed	assigned to Solugen	USPTO/FTO/expiration
multifunctional cleaner with biochelants	Justia patents	patent 12624311 listed	assigned to Solugen	commercial SKU mapping
agricultural/iron chelation/process patents	Justia patents	multiple listed	assigned patent index	family chart, licenses, trade secrets

VIII.E Insurance coverage and material exposures

not publicly verifiable confidence: low

Insurance coverage and material exposures: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-008 EC-016 EC-018

Evidence gaps

Private records needed for insurance coverage and material exposures are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering insurance coverage and material exposures.

VIII.F Material contracts

not publicly verifiable confidence: low

Material contracts: Public sources do not provide underwriting-grade evidence for this checklist section.

EC-008 EC-009 EC-010

Evidence gaps

Private records needed for material contracts are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering material contracts.

VIII.G Regulatory agency problems

partially verified confidence: medium

Regulatory agency problems: Public evidence supports selected claims, but private data-room materials are required for underwriting-grade conclusions.

EC-009 EC-018

Evidence gaps

Private records needed for regulatory agency problems are not publicly available.

Hidden risks

Public evidence may be stale, incomplete or company-originated.

Follow-up questions

Provide source documents and management explanation covering regulatory agency problems.

Regulatory / agency actions
agency or record	action or status	date or period	public evidence	diligence request
DOE LPO	conditional loan guarantee commitment	2024-06	conditions before funding	loan docs, covenants, environmental review
EPA TRI / Minetta Facility	reporting record, not enforcement action	2021 data per source	14 lbs releases across 2 chemicals	official EPA ECHO/TRI, permits, incident history
OSHA/EPA/permits	not_publicly_verifiable	current	not exhaustively searched	permit matrix, OSHA logs, agency notices

Legal and regulatory timeline Public legal/regulatory/IP milestones.

Diligence risk heatmap Risk heatmap for diligence prioritization.

Evidence

Evidence claims
ID	Claim	Status	Sources
EC-001	CB Insights lists Solugen as a $2B Houston/United States Industrials unicorn.	verified high	SRC-001
EC-002	Public web supports active private status, but absence of IPO/acquisition/shutdown is not definitive.	partially verified medium	SRC-002 SRC-008 SRC-015
EC-003	CNBC reported Solugen raised $357M in 2021 at a valuation north of $1.8B.	verified high	SRC-006
EC-004	2019 Series B release supports earlier financing and early commercial traction.	partially verified medium	SRC-007
EC-005	SEC EDGAR shows Solugen Form D notices but not a cap table.	verified high	SRC-012
EC-006	Solugen describes Bioforge as using bio-based feedstocks, engineered enzymes and metal catalysts.	verified medium	SRC-003
EC-007	Solugen markets solutions across oil/gas, renewable fuels, defense, water, cleaning, agriculture, concrete and personal care.	partially verified medium	SRC-004
EC-008	ADM/Bioforge Marshall public sources support a major scale-up and feedstock dependency.	verified high	SRC-009
EC-009	Solugen announced a $213.6M DOE LPO conditional loan guarantee commitment subject to conditions.	partially verified medium	SRC-010
EC-010	ADM, Kurita and Sasol announcements support partner traction but not revenue.	partially verified medium	SRC-009 SRC-011 SRC-018
EC-011	Solugen operates in an incumbent-dominated chemical market with biomanufacturing scale-up risk.	verified medium	SRC-006 SRC-008
EC-012	Solugen public materials describe R&D capabilities in enzyme engineering, catalysts, fermentation, pilot plant and scale-up.	verified medium	SRC-003
EC-013	Solugen public leadership page verifies co-founders and selected senior leaders.	verified medium	SRC-005
EC-014	Careers portal shows active hiring across accounting, operations, engineering, science, legal/government and defense roles.	verified medium	SRC-015
EC-015	Justia patent index shows patents assigned to Solugen across chelation, cleaning, agriculture and reactor/process topics.	partially verified medium	SRC-013
EC-016	A 2025 public docket signal identifies Verdan v. Solugen et al against Solugen and individuals.	partially verified medium	SRC-014
EC-017	Historical Solugen v. M3 litigation reached a 2021 summary-judgment opinion in part.	verified medium	SRC-016
EC-018	PlainEnviro/EPA TRI presentation reports Solugen Minetta Facility releases; this is not an enforcement finding.	partially verified medium	SRC-017

Sources
ID	Publisher	Title	Accessed
SRC-001	CB Insights	The Complete List Of Unicorn Companies	2026-06-05
SRC-002	Solugen	Our Story / About Solugen	2026-06-05
SRC-003	Solugen	Technology - Solugen	2026-06-05
SRC-004	Solugen	Solutions and market pages - Solugen	2026-06-05
SRC-005	Solugen	Leadership - Solugen	2026-06-05
SRC-006	CNBC	Solugen raises $357 million to make chemicals from sugar, not petroleum	2026-06-05
SRC-007	Renewable Carbon News	Solugen Inc. Secures $32 Million in Series B Funding	2026-06-05
SRC-008	CNBC	Solugen: 2024 CNBC Disruptor 50	2026-06-05
SRC-009	Solugen / ADM	Solugen and ADM Announce Strategic Partnership	2026-06-05
SRC-010	Solugen	Solugen Secures Conditional Commitment for $213.6M DOE Loan Guarantee	2026-06-05
SRC-011	Solugen / Kurita America	Kurita America and Solugen to Develop New Carbon-Negative Products	2026-06-05
SRC-012	U.S. Securities and Exchange Commission	SEC EDGAR company browser for Solugen, Inc. CIK 0001756965	2026-06-05
SRC-013	Justia Patents	Patents Assigned to SOLUGEN, INC.	2026-06-05
SRC-014	PACERMonitor	Verdan Procurement and Consulting v. Solugen et al	2026-06-05
SRC-015	Breezy HR / Solugen	Openings at Solugen	2026-06-05
SRC-016	Justia Law	Solugen, Inc. v. M3 Chemical Group, LLC, Document 120	2026-06-05
SRC-017	PlainEnviro, sourced from EPA TRI	SOLUGEN MINETTA FACILITY EPA Record	2026-06-05
SRC-018	Solugen / Sasol	Sasol Chemicals and Solugen evaluate sustainable ingredients	2026-06-05

Disclaimer

This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.